Actinium Pharmaceuticals Investors Alert: Class Action Update

Author: Dylan Bailey Updated: 04-18-2025 06:00 AM

Class Action Lawsuit for Actinium Pharmaceuticals Investors

Levi & Korsinsky, LLP is reaching out to investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) regarding an important class action securities lawsuit. This legal action addresses potential losses suffered by shareholders due to alleged fraudulent activity linked to the company.

Understanding the Class Action

This class action is designed to recover losses for investors adversely affected by claims of securities fraud occurring between designated dates. Allegations suggest that misleading statements were made about the company's ability to satisfy FDA guidelines concerning their radiotherapy product, Iomab-B.

Details of the Allegations

Specifically, the lawsuit contends that the defendants misrepresented critical data from the Phase 3 Sierra trial. Reports indicated that the data would not meet FDA standards necessary for the acceptance of the Iomab-B BLA. These misleading assertions have left investors vulnerable, as the reality lacked a solid basis.

Implications for Investors

For those who experienced losses in Actinium within the specified timeframe, it is crucial to note that the deadline to become a lead plaintiff in this class action is approaching. Stakeholders have until May 27, 2025, to express their interest in this role.

What Should Investors Do?

If you are a class member, there is no financial obligation to participate in this action. Your eligibility for potential compensation can occur without involving you as a lead plaintiff. Levi & Korsinsky strives to minimize costs for its clients.

Why Choose Levi & Korsinsky?

With over two decades of experience, Levi & Korsinsky has established a remarkable reputation by securing significant settlements for shareholders. The firm is recognized for its extensive expertise in complex securities litigation, employing a dedicated team of professionals to support its clients. Its recognition as a top-tier firm reinforces their commitment to investors.

Contact Information

For more details or to discuss your situation, reach out to:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Telephone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com

Frequently Asked Questions

What is the purpose of the class action lawsuit?

The lawsuit aims to recover losses for investors affected by alleged securities fraud related to Actinium Pharmaceuticals.

Who can participate in this class action?

Any shareholders of Actinium who suffered losses during the specified period can join the action.

Is there a cost to participate in the lawsuit?

No, if you are a class member, participation incurs no out-of-pocket costs.

What is the deadline to become a lead plaintiff?

The deadline to request lead plaintiff status is May 27, 2025.

How can I contact Levi & Korsinsky for more information?

You can contact them via telephone at (212) 363-7500 or visit their website at www.zlk.com for additional questions.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.